https://www.selleckchem.com/products/cadd522.html
Antimicrobial resistance (AMR) is a threat to global public health. Infections with resistant organisms are more challenging to treat, often delay patient recovery and can increase morbidity and mortality. Healthcare costs associated with treating patients with AMR organisms are poorly described. In particular, data for specific organisms, such as those harbouring carbapenem resistance, are lacking. This was a retrospective, matched (11), single-centre, cohort study at a Central London hospital, comparing costs and resource use of 442 a